New studies highlighting the promise of individualized, precision medicine were released recently at a press briefing at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).

These studies demonstrate that we are solidly in the era of precision medicine, in which patients benefit from a growing understanding of cancers genetic weak spots, said news briefing moderator Sylvia Adams, MD, Assistant Professor in the Department of Medicine at New York University Langone Medical Center. Todays findings promise to expand the range of effective, targeted treatments for people with cancer. They also affirm that patients in all settings, from research hospitals to smaller community institutions, can expect to benefit in the years ahead.

Key study findings include:

Media Resources:

About ASCO The American Society of Clinical Oncology (ASCO) is the worlds leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For more information, visit http://www.asco.org/presscenter. Patient-oriented cancer information is available atwww.cancer.net.

SOURCE: The American Society of Clinical Oncology (ASCO)

Read this article:

Studies Highlight Advances In Personalized Cancer Medicine